These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36919388)

  • 1. Post-COVID Telogen Effluvium.
    Tešanović Perković D; Vukojević M; Bukvić Mokos Z
    Acta Dermatovenerol Croat; 2022 Dec; 30(4):220-226. PubMed ID: 36919388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of patients with telogen effluvium during the pandemic: May the monocytes be responsible for post COVID-19 telogen effluvium?
    Koç Yıldırım S; Erbağcı E; Demirel Öğüt N
    J Cosmet Dermatol; 2022 May; 21(5):1809-1815. PubMed ID: 35201647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. COVID-19 infection is a major cause of acute telogen effluvium.
    Sharquie KE; Jabbar RI
    Ir J Med Sci; 2022 Aug; 191(4):1677-1681. PubMed ID: 34467470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 induced telogen effluvium.
    Aksoy H; Yıldırım UM; Ergen P; Gürel MS
    Dermatol Ther; 2021 Nov; 34(6):e15175. PubMed ID: 34708909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation.
    Hussain N; Agarwala P; Iqbal K; Omar HMS; Jangid G; Patel V; Rathore SS; Kumari C; Velasquez-Botero F; López GAB; Vishwakarma Y; Nipu AP; Ahmed NK
    J Med Virol; 2022 Apr; 94(4):1391-1401. PubMed ID: 34931698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telogen effluvium associated with COVID-19 infection.
    Olds H; Liu J; Luk K; Lim HW; Ozog D; Rambhatla PV
    Dermatol Ther; 2021 Mar; 34(2):e14761. PubMed ID: 33405302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of QR678 Neo
    Shome D; Kapoor R; Surana M; Vadera S; Shah R
    J Cosmet Dermatol; 2022 Jan; 21(1):16-23. PubMed ID: 34875139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of telogen effluvium hair loss in COVID-19 patients and its relationship with disease severity.
    Seyfi S; Alijanpour R; Aryanian Z; Ezoji K; Mahmoudi M
    J Med Life; 2022 May; 15(5):631-634. PubMed ID: 35815081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Telogen effluvium related to post severe Sars-Cov-2 infection: Clinical aspects and our management experience.
    Rizzetto G; Diotallevi F; Campanati A; Radi G; Bianchelli T; Molinelli E; Mazzanti S; Offidani A
    Dermatol Ther; 2021 Jan; 34(1):e14547. PubMed ID: 33190397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of SARS-CoV-2 infection and its vaccines in various types of hair loss.
    Aryanian Z; Balighi K; Hatami P; Afshar ZM; Mohandesi NA
    Dermatol Ther; 2022 Jun; 35(6):e15433. PubMed ID: 35266262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Red LED light therapy for telogen effluvium in the course of long COVID in patients with and without androgenetic alopecia.
    Gerkowicz A; Bartosińska J; Krakowski P; Karpiński R; Krasowska D; Raczkiewicz D; Kwasny M; Krasowska D
    Ann Agric Environ Med; 2024 Jun; 31(2):239-247. PubMed ID: 38940108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of hair loss after severe acute respiratory syndrome coronavirus 2 infection: Insight into the pathophysiology with implication for better management.
    Ohyama M; Matsudo K; Fujita T
    J Dermatol; 2022 Oct; 49(10):939-947. PubMed ID: 35633047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telogen effluvium and COVID-19: a cross-sectional study.
    Aldahish A; Vasudevan R; Salem H; Alqahtani A; AlQasim S; Alqhatani A; Al Shahrani M; Al Mohsen L; Hajla M; Calina D; Sharifi-Rad J
    Eur Rev Med Pharmacol Sci; 2023 Aug; 27(16):7823-7830. PubMed ID: 37667959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics of telogen effluvium in COVID-19 in western Iran (2020).
    Babaei K; Kavoussi H; Rezaei M; Kavoussi R
    An Bras Dermatol; 2021; 96(6):688-692. PubMed ID: 34593265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hair Loss and Telogen Effluvium Related to COVID-19: The Potential Implication of Adipose-Derived Mesenchymal Stem Cells and Platelet-Rich Plasma as Regenerative Strategies.
    Gentile P
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of autologous micrografts injection from the scalp tissue in the treatment of COVID-19 associated telogen effluvium: Clinical and trichoscopic evaluation.
    Hawwam SA; Ismail M; Elhawary EE
    Dermatol Ther; 2022 Jul; 35(7):e15545. PubMed ID: 35486375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time of onset and duration of post-COVID-19 acute telogen effluvium.
    Abrantes TF; Artounian KA; Falsey R; Simão JCL; Vañó-Galván S; Ferreira SB; Davis TL; Ridenour W; Goren A; Tosti A; Wambier CG
    J Am Acad Dermatol; 2021 Oct; 85(4):975-976. PubMed ID: 34302903
    [No Abstract]   [Full Text] [Related]  

  • 18. Post Covid telogen effluvium: the diagnostic value of serum ferritin biomarker and the preventive value of dietary supplements. a case control study.
    Bedair NI; Abdelaziz AS; Abdelrazik FS; El-Kassas M; AbouHadeed MH
    Arch Dermatol Res; 2024 Jun; 316(6):336. PubMed ID: 38844670
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Review of the post-COVID-19 syndrome associated to acute telogen effluvium].
    Chávez-Chavira G
    Rev Med Inst Mex Seguro Soc; 2023 Jul; 61(4):496-501. PubMed ID: 37540705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV-2 Infection-A Trigger Factor for Telogen Effluvium: Review of the Literature with a Case-Based Guidance for Clinical Evaluation.
    Iancu GM; Molnar E; Ungureanu L; Șenilă SC; Hașegan A; Rotaru M
    Life (Basel); 2023 Jul; 13(7):. PubMed ID: 37511952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.